0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. "We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions," Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 30, 2025 02:32 ET (06:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.